Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Why Index Weight Matters discusses the real-world effects of weighting choices on benchmarks and portfolio behavior.
21,517 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
STAG and EastGroup Properties stand out in the warehouse REIT space. This guide compares portfolio strategy, growth d...
Coinbase announced a restructuring that will cut roughly 700 positions, or 14% of its workforce, citing crypto market...
A former antitrust prosecutor who helped litigate the JetBlue-Spirit merger shares lessons for future airline regulat...
Stripe's Patrick Collison warns a surge in token theft is upending the AI startup landscape, forcing changes to free ...
Stocks all-time highs still attract buyers as earnings momentum and AI-driven demand support another leg up. Here's t...
A rare hantavirus outbreak on a expedition cruise raises travel-finance questions. Experts urge careful insurance che...
A leading XRP analyst lays out three bullish paths for XRP, each signaling multi-fold gains as crypto markets re-pric...
The latest Goldman Sachs retirement survey finds a gap between savers’ targets and retirees’ realities, prompting a c...
Susquehanna lifts Cloudflare to a $200 price target as the AI-first reset takes shape. The stock sits near $196 after...
Cardano unveils an institutional vault layer designed for tokenized capital on Cardano's chain, signaling a shift awa...
After a Q1 earnings miss, Coinbase investors are eyeing a bold growth thesis centered on subscription revenue, deriva...